Clinical Trial Update: A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation [Phase 2]

View source ↗

Summary

Phase 2 trial updating patients with chronic myeloid leukemia who switched from imatinib to nilotinib and then underwent treatment cessation; results posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Imatinib (imatinib)
• Nilotinib (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: CML | Phase 2 | Status: COMPLETED | Results posted: 2020-03-10